Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain : a prospective study
© 2019 Steunstichting ESOT..
Hepatitis C virus (HCV) positive donors are identified in Spain by antibody detection (HCV-Ab) techniques while a HCV nuclear acid-testing (HCV-NAT) is not mandatory. Since it has been shown that HCV-Ab positive HCV-NAT negative donors do not universally transmit the infection, we designed a protocol based on the identification of viremia in HCV-Ab positive donors to start treatment if needed. HCV-Ab-positive donors were identified and we performed HCV-NAT immediately. Donors coinfected with HIV were excluded. Recipients with a low chance to receive a transplant, with no history of liver disease and who were negative for HCV-Ab were selected after informed consent was signed. Kidney recipients from HCV-NAT-positive donors received glecaprevir and pibrentasvir from 6 h before the transplant until 8 weeks after. Recipients from HCV-NAT-negative donors were not treated. Regular monitoring by HCV-NAT was performed to initiate antiviral treatment. We included 11 recipients from six deceased donors Four recipients received grafts from HCV-NAT-positive donors and seven patients received grafts from HCV-NAT-negative donors. None of our recipients exhibited HCV-NAT positivity during the minimum follow-up period of 6 months. Recipients from HCV-NAT-positive donors exhibited sustained virologic response at 12 weeks. One recipient from an HCV-NAT-negative donor lost his graft via a process thought to be unrelated to HCV. The remaining 10 patients had a stable functioning graft at the end of the follow-up period. Our preliminary data suggest that renal transplantation from HCV-Ab- positive donors to HCV-Ab negative recipients is safe when only the recipients of organs from HCV-NAT-positive donors are treated.
| Errataetall: |
CommentIn: Transpl Int. 2019 Jul;32(7):690-692. - PMID 30920681 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Transplant international : official journal of the European Society for Organ Transplantation - 32(2019), 7 vom: 30. Juli, Seite 710-716 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franco, Antonio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.02.2020 Date Revised 04.12.2021 published: Print-Electronic CommentIn: Transpl Int. 2019 Jul;32(7):690-692. - PMID 30920681 Citation Status MEDLINE |
|---|
| doi: |
10.1111/tri.13410 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293990883 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293990883 | ||
| 003 | DE-627 | ||
| 005 | 20231225080524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tri.13410 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0979.xml |
| 035 | |a (DE-627)NLM293990883 | ||
| 035 | |a (NLM)30773693 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franco, Antonio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain |b a prospective study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.02.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Transpl Int. 2019 Jul;32(7):690-692. - PMID 30920681 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 Steunstichting ESOT. | ||
| 520 | |a Hepatitis C virus (HCV) positive donors are identified in Spain by antibody detection (HCV-Ab) techniques while a HCV nuclear acid-testing (HCV-NAT) is not mandatory. Since it has been shown that HCV-Ab positive HCV-NAT negative donors do not universally transmit the infection, we designed a protocol based on the identification of viremia in HCV-Ab positive donors to start treatment if needed. HCV-Ab-positive donors were identified and we performed HCV-NAT immediately. Donors coinfected with HIV were excluded. Recipients with a low chance to receive a transplant, with no history of liver disease and who were negative for HCV-Ab were selected after informed consent was signed. Kidney recipients from HCV-NAT-positive donors received glecaprevir and pibrentasvir from 6 h before the transplant until 8 weeks after. Recipients from HCV-NAT-negative donors were not treated. Regular monitoring by HCV-NAT was performed to initiate antiviral treatment. We included 11 recipients from six deceased donors Four recipients received grafts from HCV-NAT-positive donors and seven patients received grafts from HCV-NAT-negative donors. None of our recipients exhibited HCV-NAT positivity during the minimum follow-up period of 6 months. Recipients from HCV-NAT-positive donors exhibited sustained virologic response at 12 weeks. One recipient from an HCV-NAT-negative donor lost his graft via a process thought to be unrelated to HCV. The remaining 10 patients had a stable functioning graft at the end of the follow-up period. Our preliminary data suggest that renal transplantation from HCV-Ab- positive donors to HCV-Ab negative recipients is safe when only the recipients of organs from HCV-NAT-positive donors are treated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a direct acting antiviral agents | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a nuclear acid testing | |
| 650 | 4 | |a renal transplantation | |
| 650 | 4 | |a seronegative recipient | |
| 650 | 4 | |a viremia | |
| 650 | 7 | |a Aminoisobutyric Acids |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Hepatitis C Antibodies |2 NLM | |
| 650 | 7 | |a Lactams, Macrocyclic |2 NLM | |
| 650 | 7 | |a Pyrrolidines |2 NLM | |
| 650 | 7 | |a Quinoxalines |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a pibrentasvir |2 NLM | |
| 650 | 7 | |a 2WU922TK3L |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a glecaprevir |2 NLM | |
| 650 | 7 | |a K6BUU8J72P |2 NLM | |
| 700 | 1 | |a Moreso, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho, Asunción |e verfasserin |4 aut | |
| 700 | 1 | |a Kanter, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Gimeno, Adelina |e verfasserin |4 aut | |
| 700 | 1 | |a Balibrea, Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Perez Contreras, Francisco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant international : official journal of the European Society for Organ Transplantation |d 1992 |g 32(2019), 7 vom: 30. Juli, Seite 710-716 |w (DE-627)NLM012972258 |x 1432-2277 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2019 |g number:7 |g day:30 |g month:07 |g pages:710-716 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tri.13410 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2019 |e 7 |b 30 |c 07 |h 710-716 | ||